Clinical Characteristics of Metastatic Prostate Cancer Patients Infected with COVID-19 in South Italy
| Autor: | Gianluca Ragone, Carlo Buonerba, Ciro Imbimbo, Antonella Sciarra, Giuseppe Di Lorenzo, Roberto Sanseverino, Concetta Ingenito, Emilio Leo, Sabino De Placido, Annamaria Libroia, Felice Crocetto, Simona Iaccarino, Giorgio Napodano, Luciana Buonerba, Zisis Kozlakidis |
|---|---|
| Přispěvatelé: | Di Lorenzo, G, Buonerba, L, Ingenito, C, Crocetto, F, Buonerba, C, Libroia, A, Sciarra, A, Ragone, G, Sanseverino, R, Iaccarino, S, Napodano, G, Imbimbo, C, Leo, E, Kozlakidis, Z, De Placido, S, Di Lorenzo, G., Buonerba, L., Ingenito, C., Crocetto, F., Buonerba, C., Libroia, A., Sciarra, A., Ragone, G., Sanseverino, R., Iaccarino, S., Napodano, G., Imbimbo, C., Leo, E., Kozlakidis, Z., De Placido, S. |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_treatment Disease Comorbidities Prostate cancer 0302 clinical medicine 030212 general & internal medicine Androgen Antagonist Aged 80 and over General Medicine Middle Aged Hospitalization Prostatic Neoplasms Castration-Resistant Italy 030220 oncology & carcinogenesis Urologic cancer Disease Progression Hormonal therapy Drug Therapy Combination Comorbiditie Human medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Prognosi Drug interaction Coronavirus disease SARS-CoV-2 Pneumonia Viral Protective factor Clinical Trial Note 03 medical and health sciences Internal medicine medicine Risk factor Aged Antiviral Agent Chemotherapy Betacoronaviru Pandemic business.industry Coronavirus Infection Heparin SARS-CoV-2 Risk Factor COVID-19 medicine.disease business |
| Zdroj: | Oncology |
| Popis: | Background: To date, the clinical characteristics of coronavirus disease 19 (COVID-19)-infected urologic cancer patients are unknown. Methods: We have analyzed all patients with prostate cancer undergoing hormonal or chemotherapy treatment and receiving telephone and in person pre-triage between March 1 and 27, 2020, at the Tortora Hospital, Pagani, Italy. Results: Among 72 patients, 48 and 24 were hormone-sensitive (HS) and castration-resistant prostate cancer (CRPC), respectively; 0 HS and 2 (8.3%) CRPC (p < 0.05) were positive for COVID-19. Both patients were receiving LHRH agonist therapy, and 1 patient was receiving enzalutamide. Urgent intensive care unit admission was required due to clinical worsening. Blood tests showed severe lymphopenia, anemia, and an increase in platelets. Retroviral therapy, antibiotics, heparin, and chloroquine were prescribed at the beginning. One patient also received tocilizumab as a salvage treatment. After 3 weeks of hospitalization, the patients were discharged from the hospital. Both patients suffered from an aggressive COVID-19 course due to concomitant comorbidities. Conclusions: Investigating whether hormonal therapy, especially in advanced disease, acts as a protective factor or a risk factor during COVID-19 could be useful. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|